Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapyMarjan Mojtabavi Naeini, Nicola Waddell, Felicity Newell et al.|Nature Communications|2023Cited by 31
Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancerSwetha Sridharan, Jarad Martin, Fiona Day et al.|Radiation Oncology|2022Cited by 7
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Jarad Martin, Stephen R. Thompson et al.|BMC Cancer|2022Cited by 6
The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodologyChristine Paul, Shanthi Ramanathan, Nicole M. Verrills et al.|BMC Health Services Research|2024Cited by 1
280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPYMarjan Mojtabavi Naeini, Nicola Waddell, Felicity Newell et al.|Diseases of the Esophagus|2022Cited by 0